Faut-il faire une chimiothérapie néo-adjuvante dans les cancers de l'estomac ? = Is neo-adjuvant chemotherapy necessary in the cancer of the stomachYCHOU, M.Annales de gastroénterologie et d'hépatologie. 1995, Vol 31, Num 2, pp 132-133, issn 0066-2070Article

Chimiothérapie dans les cancers de l'estomac : une réalité ? = Chemotherapy of gastric cancersYCHOU, M.Pathologie et biologie. 1994, Vol 42, Num 10, pp 1020-1021, issn 0369-8114Conference Paper

Faut-il faire un traitement d'induction dans les cancers du cardia opérables ? = Is there a need for induction treatment of operable cardia cancers ?YCHOU, M.Bulletin du cancer. 1997, Vol 84, Num 10, pp 988-990, issn 0007-4551Article

Actualités sur le CPT-11 et chirurgie des métastases hépatiques de cancer colorectal : à l'ESMO 2002 (Nice, 18-22 octobre 2002) = Topics about CPT-11 liver metastases surgery of colorectal cancers : l'ESMO 2002 (Nice, 2003, october 18-22)SPANO, J. P; YCHOU, M.La Lettre du cancérologue (Boulogne). 2003, Vol 12, Num 2, pp 2-4, issn 1165-113X, 3 p., SUPArticle

Le point sur les traitements adjuvants et néoadjuvants des adénocarcinomes œsogastriques : Les cancers digestifs = Adjuvant and neoadjuvant treatments in gastroesophageal adenocarcinomas : a reviewSAMALIN, E; YCHOU, M.Oncologie (Paris). 2008, Vol 10, Num 3, pp 175-181, issn 1292-3818, 7 p.Article

Quelle stratégie thérapeutique pour le cancer gastrique localement avancé ? = Combined treatment in locally advanced gastric cancerASSENAT, E; YCHOU, M.Oncologie (Paris). 2003, Vol 5, Num 2, pp 58-62, issn 1292-3818, 5 p.Article

Value of serial carcinoembryonic antigen levels in evaluating the response to chemotherapy in patients with advanced digestive cancersYCHOU, M; DUFFOUR, J; KRAMAR, A et al.Oncology reports. 1998, Vol 5, Num 5, pp 1245-1250, issn 1021-335XArticle

Le statut tumoral KRAS doit-il faire changer la stratégie thérapeutique des patients avec cancer colorectal métastatique (CCRM) ? = Impact of mutatronal status of KRAS in the care of patients with colorectal cancer metastasisASSENAT, E; YCHOU, M.Bulletin du cancer. 2009, Vol 96, Num DEC, issn 0007-4551, S41-S46, NSArticle

Les cancers digestifs = Digestive cancerYCHOU, M.La Lettre du cancérologue (Boulogne). 2004, Vol 13, Num 5, pp 15-18, issn 1165-113X, 4 p., SUP2Conference Paper

Echec de l'acetate d'elliptinium dans le traitement de l'hépatocarcinome inopérable (essai phase II) = Elliptinium acetate for the treatment of unresectable hepatomaROUGIER, P; YCHOU, M; DROZ, J. P et al.Bulletin du cancer. 1988, Vol 75, Num 10, pp 979-981, issn 0007-4551Article

Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancerCONROY, T; VIRET, F; PEIFFERT, D et al.British journal of cancer. 2008, Vol 99, Num 9, pp 1395-1401, issn 0007-0920, 7 p.Article

Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancerFALLIK, D; YCHOU, M; DUCREUX, M et al.Annals of oncology. 2003, Vol 14, Num 6, pp 856-863, issn 0923-7534, 8 p.Article

Quels sont les examens à réaliser dans le bilan d'extension pré-thérapeutique ? Critères de qualité et résultats attendus. Commentaire = What exams should be ordered for the pretherapeutic work-up ? Criteria of quality and expected results. CommentaryGALLIX, Benoit.Gastroentérologie clinique et biologique. 2003, Vol 27, pp 9-10, issn 0399-8320, 18 p., HS2Article

Peut-on rendre résécables des métastases hépatiques initialement non résécables ? Commentaire = Can initially non-resectable hepatic métastases be made resectable? CommentaryRIVOIRE, Michel.Gastroentérologie clinique et biologique. 2003, Vol 27, pp 18-19, issn 0399-8320, 19 p., HS2Article

Chemotherapy in carcinomas of unknown primary site : A high-dose intensity policyCULINE, S; FABBRO, M; YCHOU, M et al.Annals of oncology. 1999, Vol 10, Num 5, pp 569-575, issn 0923-7534Article

Actualités en gastroentérologie = Data in gastroenterologyYCHOU, M; SENESSE, P; QUENET, F et al.Bulletin du cancer. 1998, Vol 85, Num 1, pp 37-41, issn 0007-4551Article

Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumorsCULINE, S; FABBRO, M; ASSENS, C et al.Annals of oncology. 1997, Vol 8, Num 10, pp 951-956, issn 0923-7534Article

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidinesMACHOVER, D; DIAZ-RUBIO, E; ABAD, A et al.Annals of oncology. 1996, Vol 7, Num 1, pp 95-98, issn 0923-7534Article

Intérêt des marqueurs tumoraux en cancérologie digestive = Tumor markers in digestive malignant diseasesYCHOU, M; ROUGIER, P; BIDART, J. M et al.La Semaine des hôpitaux de Paris. 1990, Vol 66, Num 10, pp 527-533, issn 0037-1777Article

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)DUCREUX, M; ADENIS, A; CONROY, T et al.European journal of cancer (1990). 2013, Vol 49, Num 6, pp 1236-1245, issn 0959-8049, 10 p.Article

Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOXMAZARD, T; YCHOU, M; THEZENAS, S et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 3, pp 807-814, issn 0344-5704, 8 p.Article

Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatmentSAMALIN, E; AFCHAIN, P; BOUCHE, O et al.Clinics and research in hepatology and gastroenterology (Print). 2011, Vol 35, Num 1, pp 48-54, issn 2210-7401, 7 p.Article

Cancer colorectal métastatique: repousser les limites de la résécabilité = Metastatic colorectal cancer: extending the limits of resectabilityADAM, R; SA CUNHA, A; YCHOU, M et al.Journal de chirurgie viscérale (Print). 2011, Vol 148, issn 1878-786X, S17-S23, SUP2Article

A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancerYCHOU, M; HOHENBERGER, W; THEZENAS, S et al.Annals of oncology. 2009, Vol 20, Num 12, pp 1964-1970, issn 0923-7534, 7 p.Article

Efficacité d'un traitement par analogues de la somatostatine en monothérapie dans la prise en charge d'une tumeur endocrine métastatique = Efficacy of prolonged-release somatostatin analog monotherapy in metastatic endocrine tumorsKANYINDA-K, J.-M; SAMALIN, E; SEBAH, H et al.Gastroentérologie clinique et biologique. 2008, Vol 32, Num 12, pp 989-991, issn 0399-8320, 3 p.Article